US biotech major Biogen (Nasdaq: BIIB) today reported third quarter 2022 financial results that were better than investors expected, but the stock fell 2.3% to $267.84 in early trading.
Third quarter total revenue of $2.51 billion decreased 10% versus the prior year at actual currency and 8% at constant currency, but exceeded consensus estimates of $2.47 billion.
Third quarter generally accepted accounting principles (GAAP) net income and diluted earnings per share (EPS) attributable to Biogen were $1.14 billion and $7.84, respectively. Third quarter non-GAAP net income and diluted EPS attributable to Biogen were $691 million and $4.77, respectively. The latter figure exceeded expectations of $4.13 per share.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze